References
- Caminero JA and Torres A. Controversial topics in tuberculosis. Eur Respir J. 2004; 24: 895. DOI: 10.1183/09031936.04.00111204
- WHO. Global Tuberculosis Report 2016 Update. Accessed January 2017.
- WHO.
TB–a global emergency. WHO Press Release: WHO/31 . Geneva: World Health Organization; 1993. - Anderson L, Dean A, Falzon D, et al.
Global Tuberculosis Report 2015 . 20th ed. Geneva: World Health Organization; 2015. - Caminero Luna JA. In: Disease IUATaL, editor.
Guía de la tuberculosis para médicos especialistas . Paris: Imprimerie Chirat. 2003; 1–390. - Nunn AJ, Jindani A and Enarson DA. Results at 30 months of a randomized trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011; 15: 741–45. DOI: 10.5588/ijtld.10.0392
- East African/British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet. 1974; 2: 237–40
- Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013; 42: 169–79. DOI: 10.1183/09031936.00136312
- Falzon D, Gandhi N and Migliori GB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013; 42: 156–68. DOI: 10.1183/09031936.00134712
- Falzon D, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 2011; 38: 516–528. DOI: 10.1183/09031936.00073611
- Mishra GP. Treatment of drug-resistant tuberculosis. Lancet Infect. 2011; 11(9): 659–660. DOI: 10.1016/S1473-3099(11)70225-0
- WHO. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015; 2014.
http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1 . Accessed February 10, 2017. - Hargreaves NJ, Kadzakumanja O, Whitty CJ, Salaniponi FM, Harries AD and Squire SB. “Smear-negative” pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int. J. Tuberc. Lung. 2001; 5: 847–854.
- Perkins MD and Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J. Infect. 2007; 196(Suppl 1): S15–S27. DOI: 10.1086/518656
- WHO. Tuberculosis diagnostics technology and market landscape; 2014.
http://unitaid.org/images/marketdynamics/publications/UNITAID_TB_Diagnostics_Landscape_3rd-edition.pdf . Accessed March 5, 2017. - McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis. 2012; 205(Suppl 2): S147–S58. DOI: 10.1093/infdis/jir860
- Sollai S, Galli L, de Martino M and Chiappini E. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: 2013 update. BMC Infectious Diseases. 2014; 14(Suppl 1): S6. DOI: 10.1186/1471-2334-14-S1-S6
- Qiagen. QIAGEN launches QuantiFERON®-TB Gold Plus – a new generation of the most accurate test for detecting tuberculosis infections 2015.
https://www.qiagen.com/de/about-us/press-releases/pressreleaseview?ID={C861949E-DF50-475B-8148-B4C70034C49E}&lang=en . Accessed June 16 2016. - Barcellini L, Borroni E, et al. First independent evaluation of QuantiFERON-TB Plus performance. Eur Respir J. 2016; 47: 1587–90. DOI: 10.1183/13993003.02033-2015
- Knierer J, Gallegos Morales EN, Schablon A, Nienhaus A and Kersten JF. QFT-Plus: a plus in variability? – Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. Journal of Occupational Medicine and Toxicology. 2017; 12: 1. DOI: 10.1186/s12995-016-0148-z
- CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2010; 59: 1–25.
- WHO. WHO Guidelines on the management of latent tuberculosis infection.
http://www.who.int/tb/publications/latent-tuberculosis-infection/en/ . Accessed March 2, 2017. - National Institute for Health and Clinical Excellence.
uberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control . London: National Institute for Health and Clinical Excellence; 2011 (http://www.nice.org.uk/nicemedia/live/13422/53642/53642.pdf ). Accessed November 7, 2016. - European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis.
http://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf . Accessed November 10, 2016. - WHO.
Guidance for national tuberculosis programmes on the management of tuberculosis in children . WHO; 2006. Accessed October 7, 2016. - Shingadia D and Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis. 2003; 3: 624–632. DOI: 10.1016/S1473-3099(03)00771-0
- Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A, Girmachew F, et al. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. Int J Tuberc Lung Dis. 2010; 14: 1259–1265.
- WHO. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB).
http://www.who.int/tb/laboratory/line_probe_assays/en . Accessed September 2016. - Hillemann D, Weizenegger M, Kubica T, Richter E and Niemann S. Use of genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2005; 43: 369–703. DOI: 10.1128/JCM.43.8.3699-3703.2005
- WHO.
Tuberculosis diagnostics technology and market landscape . 3rd ed. Geneva: World Health Organization; 2014. Accessed November 12, 2016. - Brossier F, Veziris N, Aubry A, Jarlier V and Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrugresistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2010; 48: 1683–9. DOI: 10.1128/JCM.01947-09
- Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38: 516–28. DOI: 10.1183/09031936.00073611
- WHO.
The treatment of tuberculosis: guidelines – 4th ed. Document WHO/HTM/TB/2009.420 . Geneva: World Health Organization; 2010. Accessed December 1, 2016. - WHO.
Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402 . Geneva, World Health Organization; 2008. Accessed September 10, 2016. - WHO. Companion handbook to the WHO guidelines for the programmatic management of drug resistant tuberculosis.
http://www.who.int/tb/publications/pmdt_companionhandbook/en . Accessed September 15 2016. - WHO.
Global Tuberculosis Report. 2016 Update . World Health Organization; 2016. Accessed March 13, 2017. - WHO. WHO treatment guidelines for drugs-resistant tuberculosis. 2016 update.
http://www/who.int/MDRTBguidelines2016.pdf . Accessed March 13, 2017. - CDC. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013; 62:1–12.
- Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009; 53: 1290–1292. DOI: 10.1128/AAC.01393-08
- Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med. 2009; 180: 553–557. DOI: 10.1164/rccm.200807-1152OC
- >Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360: 2397–2405. DOI: 10.1056/NEJMoa0808427
- Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371: 723–732. DOI: 10.1056/NEJMoa1313865
- Cox E and Laessig K. FDA approval of bedaquiline: the benefit-riskbalance for drug-resistant tuberculosis. N Engl J Med. 2014; 371(8): 689–691. DOI: 10.1056/NEJMp1314385
- Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015; 60: 188–194. DOI: 10.1093/cid/ciu786
- Hartkoorn RC, Uplekar S and Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014; 58: 2979–2981. DOI: 10.1128/AAC.00037-14
- Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366: 2151–2160. DOI: 10.1056/NEJMoa1112433
- Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011; 15: 949–954. DOI: 10.5588/ijtld.10.0616
- Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. EurRespir J. 2013; 41: 1393–1400. DOI: 10.1183/09031936.00125812
- Esposito S, D’Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J. 2014; 44: 811–815. DOI: 10.1183/09031936.00060414
- Esposito S, Bianchini S and Blasi F. Bedaquiline and delamanid intuberculosis. Expert Opin Pharmacother. 2015; 16(15): 2319–2330. DOI: 10.1517/14656566.2015.1080240
- Lange C, Abubakar I, Alffenaar J-WC, et al. Management of patients with multidrug resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014; 44(1): 23–63. DOI: 10.1183/09031936.00188313
- Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367: 1508–18. DOI: 10.1056/NEJMoa1201964
- Tang S, Yao L, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China. Eur Respir J. 2015; 45: 161–70. DOI: 10.1183/09031936.00035114
- Chang KC, Yew WW, Tam CM and Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review and cohort analysis and meta-analysis. Antimicrob Agents Chemother. 2013; 57: 4097–104. DOI: 10.1128/AAC.00120-13
- Sorgiu G, Centis R, D’Ambrosio L, Alffenaar JWC, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012; 40: 1430–42. DOI: 10.1183/09031936.00022912
- Ntziora F and Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: A systematic review. Int J Tuberc Lung Dis. 2007 Aug; 11(8): 936.
- Zhang M, Sala C, Dhar N, et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014; 58: 3217–23. DOI: 10.1128/AAC.02410-14
- Louie A, Eichas K, Files K, et al. Activities of PNU-100480 (PNU 480) alone, PNU 480 plus its major metabolite PNU-101603 (PNU 1603) and PNU 480 plus PNU 1603 in combination with rifampin (RIF) against Mycobacterium tuberculosis: comparison with linezolid. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011; Sept 17–20: A1–1737. Chicago, IL.
- Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014; 9:
e94462 . DOI: 10.1371/journal.pone.0094462 - Caminero JA, van Deun A, Fujiwara PI, Monedero I, Chiang CY, Rieder HL, et al.
Guidelines for clinical and operational management of drug-resistant tuberculosis . Paris: International Union Against Tuberculosis and Lung Disease. 2013; 1–232. - Caminero JA, Sotgiu G, Zumla A and Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010; 10: 621–9. DOI: 10.1016/S1473-3099(10)70139-0
- WHO. Global Tuberculosis Report. 2016 Update. Accessed March 13, 2017.
- Piubello A, Harouna SH, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014 Oct; 18(10): 1188–94. DOI: 10.5588/ijtld.13.0075
- Aung KJ, Van Deun A, et al. 9-month Bangladesh regimen for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014 Oct; 18(10): 1180–7. DOI: 10.5588/ijtld.14.0100
DOI: https://doi.org/10.5334/aogh.2415 | Journal eISSN: 2214-9996
Language: English
Published on: Jan 22, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2019 B. Rojano, J. A. Caminero, M. Hayek, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.